ストックスクリーナーアプリを入手
29.32
3.04%
-0.92
プレマーケット:
28.92
-0.40
-1.36%
前日終値:
$30.24
開ける：
$29.36
24時間の取引高:
12.71M
Relative Volume:
0.65
時価総額：
$6.79B
収益：
$2.35B
当期純損益:
$128.37M
株価収益率:
56.16
EPS:
0.5221
ネットキャッシュフロー:
$57.42M
1週間 パフォーマンス:
-10.42%
1か月 パフォーマンス:
-13.61%
6か月 パフォーマンス:
+2.27%
1年 パフォーマンス:
-50.03%
1日の値動き範囲:
$27.61
$30.00
1週間の範囲:
$27.61
$35.85
52週間の値動き範囲:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Compare HIMS vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
29.32 | 7.00B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
17.52 | 55.69B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.27 | 43.77B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.67 | 36.19B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.51 | 32.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
523.63 | 26.29B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-24 | 開始されました | JP Morgan | Overweight |
| 2026-03-10 | アップグレード | BofA Securities | Underperform → Neutral |
| 2026-03-10 | アップグレード | Citigroup | Sell → Neutral |
| 2026-03-09 | アップグレード | Needham | Hold → Buy |
| 2026-02-24 | ダウングレード | BTIG Research | Buy → Neutral |
| 2026-01-12 | 開始されました | Evercore ISI | In-line |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-10-21 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | ダウングレード | Needham | Buy → Hold |
| 2025-06-04 | 繰り返されました | Needham | Buy |
| 2025-04-29 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | ダウングレード | Citigroup | Neutral → Sell |
| 2025-01-07 | 開始されました | BTIG Research | Buy |
| 2024-12-17 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-14 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-08-22 | 開始されました | Needham | Buy |
| 2024-08-09 | ダウングレード | Imperial Capital | Outperform → In-line |
| 2024-05-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-04-16 | ダウングレード | Jefferies | Buy → Hold |
| 2024-04-10 | 開始されました | Canaccord Genuity | Buy |
| 2024-02-28 | アップグレード | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 開始されました | Leerink Partners | Market Perform |
| 2023-12-07 | 開始されました | Imperial Capital | In-line |
| 2023-07-28 | 開始されました | TD Cowen | Outperform |
| 2023-04-11 | 開始されました | Robert W. Baird | Neutral |
| 2023-02-09 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-08 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 開始されました | Truist | Hold |
| 2022-07-15 | 開始されました | SVB Leerink | Underperform |
| 2022-04-14 | 開始されました | Guggenheim | Buy |
| 2022-04-01 | 再開されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | Deutsche Bank | Hold |
| 2021-12-02 | 開始されました | Jefferies | Hold |
| 2021-11-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 開始されました | BofA Securities | Neutral |
| 2021-05-20 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 開始されました | Truist | Hold |
| 2021-03-09 | 開始されました | Credit Suisse | Neutral |
| 2021-03-02 | アップグレード | Citigroup | Neutral → Buy |
| 2021-02-17 | 開始されました | Citigroup | Neutral |
| 2021-02-12 | 開始されました | Piper Sandler | Neutral |
| 2021-02-08 | 開始されました | Tigress Financial | Buy |
すべてを表示
Hims Hers Health Inc (HIMS) 最新ニュース
Hims & Hers leverages AI and vertical integrati... - Pluang
Understanding The AI Flywheel At Hims And Hers (NYSE:HIMS) - Seeking Alpha
HIMS Stock Rises Overnight: Retail Traders Bet On Peptides Upside After FDA Panel Backs 6 Of 7 Compounds - Stocktwits
Hims & Hers Health Stock (HIMS) Opinions on FDA Peptide Decisions - Quiver Quantitative
Why Is HIMS Stock Rallying 13% Today? - Stocktwits
A Hims cofounder fired his entire marketing team for AI. Now his 24/7 online vet service is growing 20% a month - Yahoo Finance
FDA Panel Narrowly Backs Four Peptides — Hims & Hers Stock in the Spotlight - Yahoo Finance
Hims & Hers Health (HIMS) Shares Fall After FDA Panel's Negative Vote on Emideltide - GuruFocus
HIMS Maintains by Truist Securities -- Price Target Raised to $2 - GuruFocus
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know - Yahoo Finance
HIMS Stock Sinks as FDA Gives Hims & Hers Peptide the Cold Shoulder - Yahoo Finance
Hims & Hers (HIMS) Stock Looks Cheap On Cash Flow But Pricey After A 313% Run - Yahoo Finance
HIMS Stock Dives Sharply as Uninsured Patients Raise Concerns while FDA Process Remains Uncertain - FXLeaders
HIMS Stock Falls Over 10% Amid Market Fluctuations - GuruFocus
Hims & Hers down as FDA advisors snub first peptide (HIMS:NYSE) - Seeking Alpha
Hims & Hers Health upgraded to Buy on strong op... - Pluang
Is Today’s Dip a Buying Opportunity for Hims & Hers Health (HIMS) Stock? - TipRanks
Hims & Hers Health Slides as Traders Fade Peptide Rally - Quiver Quantitative
Hims & Hers: Peptide Ruling A Positive, Operational Good Sense Makes 'Buy' Case (Upgrade) - Seeking Alpha
HIMS Stock Climbs Overnight As FDA Advisory Panel Backs 4 Peptides — ‘Pharma Bro’ Martin Shkreli Goes Short - Stocktwits
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now? - Yahoo Finance
Peptide catalyst lift for Hims & Hers (NYSE:HIMS) limited by FDA review timetable - TechStock²
Hims & Hers Health: Favorable Decision on Peptides Lifts Investor Appetite but Uncertainty Very High - Morningstar
Telehealth firms urge FDA to legalize peptides, with guardrails - Crain's New York
What Shapes Hims & Hers Health (NYSE:HIMS) Russell 2000 View? - Kalkine Media
FDA Peptide Shift And Leadership Change Could Be A Game Changer For Hims & Hers Health (HIMS) - simplywall.st
Is It Too Late to Buy Hims & Hers Health Inc (HIMS) After 3.4% R - GuruFocus
Hims & Hers Health, Inc. Stock 12‑Month Price Target Raised to $30.38, Implies 4% Downside - TradingView
Hims & Hers Health (HIMS) Gains On FDA Panel News, Is The Valuation Gap Still Wide? - Yahoo Finance
HIMS Maintained by Citigroup -- Price Target Raised to $35.00 - GuruFocus
What the FDA’s Peptide Decision Means for Hims & Hers’ Long-Term Telehealth Strategy - Barron's
Hims & Hers Stock Jumps 13% After FDA Panel Backs BPC-157 for Compounding - finance.biggo.com
Hims & Hers Health, Inc. stock Analysis: FDA Catalyst Impacts Neutral Regime - The Cryptonomist
FDA advisers back first of seven peptides under review for looser rules - Reuters
Hims & Hers Health (NYSE:HIMS) rises as FDA BPC-157 decision turns market attention to revenue per subscriber - TechStock²
HIMS Shares Surge Over 10% Following FDA Panel Decision - GuruFocus
HIMS Stock Surges Following FDA Advisory Panel Decision - GuruFocus
Hims & Hers gains as FDA panel endorses peptide BPC-157 (HIMS) - Seeking Alpha
Hims & Hers Health shares jump on FDA’s push to expand BPC-157 access - Investing.com Canada
Hims & Hers stock jumps after FDA panel backs BPC-157 access - Investing.com Canada
Hims & Hers stands to gain if the FDA loosens restrictions on peptides - Reuters
Telehealth Firms Urge FDA to Legalize Peptides, With Guardrails - Bloomberg.com
$Hims & Hers Health (HIMS.US)$ - Moomoo
Hims & Hers Health Inc (HIMS) Shares Fall 3.2% -- What GF Score of 83 Tells Investors - GuruFocus
Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
HIMS Stock Slips Overnight: Hims & Hers Bulks Up Debt Raise To $350M For Eucalyptus Buyout, AI Push - Stocktwits
The FDA Is About to Weigh in on the Great Peptide Debate - inc.com
Form 144 Hims & Hers Health For: 22 July By Investing.com - Investing.com Canada
Hims & Hers Health, Inc. SEC Filing (Jul 22, 2026) - Stock Titan
HIMS Sees Surge in App Downloads Amid Peptide Opportunity - GuruFocus
HIMS Stock Snaps 3-Day Losing Streak: FDA Adds 8 New Peptide Voters Deemed ‘More Qualified And Less Conflicted’ - Stocktwits
Hims Hers Health Inc (HIMS) 財務データ
収益
当期純利益
現金流量
EPS
4.23%
0.43%
大文字化:
|
ボリューム (24 時間):